Hayat ÖZKANAY

Dr. Hayat ÖZKANAY

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2026 in Turkish Journal of Immunology
Verified
Journal Article
Closed access
RARasime Derya Aksoy
Rasime Derya Aksoy
CBCigdem Eda Balkan Bozlak
Cigdem Eda Balkan Bozlak
KBKemal Bilgin
Kemal Bilgin
ABAsuman Birinci
Asuman Birinci
BÇBuket Şeflek Çetin
Buket Şeflek Çetin
AZAyse Gul Zamani
Ayse Gul Zamani
Objective: Panel-reactive antibodies (PRA) or anti-human leucocyte antigens (anti-HLAs) are produced by the patient's immune system in response to donors during transplant procedures. Antibodies to HLA are known to develop following blood transfusion, pregnancy, and a history of transplantation. Donor-specific antibodies (DSA) arising in patient serum in response to donor-specific HLA can be detected using the single antigen bead (SAB) test. The objective of this multicentre retrospective study is to analyse the distribution of anti-HLA antibodies in Turkey, mean fluorescence intensity (MFI) values, and to assess the concordance of PRA tests across centres on a national scale. Materials and Methods: The study will include adult patients and their donors who were on the living and cadaveric waiting lists and who underwent PRA screening/identification/SAB tests between 2013-2024. Data on patients' anti-HLA antibodies and demographics will be obtained from 12 tissue typing laboratories. Tests and MFI values will be recorded. The data will undergo rigorous testing for statistical significance using SPSS version 23.0, with a p-value <0.05. Results: This study will reveal the distribution of anti-HLA antibodies across Turkey for the first time, and the effects of sensitization factors will be analysed. The correlation between Class I and II antibody positivity, MFI levels, and demographic data will be evaluated. Discussion: The findings of this study will contribute to advancing laboratory consistency and establishing national test standardisation. It is hypothesized that the obtained data may also provide insights into updating the organ allocation system to include antibody testing. The comparison of PRA tests, SAB methods, and the MFI values will provide a new perspective on laboratory and clinical evaluation. This study aims to enhance the efficacy of patient-donor matching through the identification of shared criteria for pre-transplant immunological risk assessment within the national context. Keywords: MFI, PRA screening/identification, SAB, transplantation

24 July 2025 in Medicina
Verified
Journal Article
Open access
PDF file
MYMelike Yüksel Yavuz
Melike Yüksel Yavuz
OTOnur Turan
Onur Turan
HÖHayat ÖZKANAY
Hayat ÖZKANAY
MKMehmet Köseoğlu
Mehmet Köseoğlu
Background and Objectives: Asthma, COPD, and asthma–COPD overlap are obstructive lung diseases with inflammation at their core. Oxidative stress and impaired antioxidant balance play a significant role in etiopathogenesis. This study aimed to determine whether there are differences in total antioxidant capacity (TAC) between asthma, COPD, and asthma–COPD overlap. Materials and Methods: A total of 76 patients participated in this prospective cross-sectional study. TAC levels in fasting venous blood samples were measured using a biochemistry analyzer and the total antioxidant activity method (Architect C1600, Abbott Laboratories, IL, USA). Results: TAC levels were lower in COPD patients compared to asthma and ACO patients (p = 0.049 and 0.026, respectively). TAC levels were lower in current and former smokers compared to never smokers (p = 0.033). There was no significant correlation between TAC level and eosinophil count (p = 0.597) and FEV1 and FEV1/FVC (p = 0.372 and p = 0.189). Conclusions: Our results suggest that TAC levels may serve as a marker to differentiate COPD from asthma or ACO.